TheraRadar

Vyne

Pre-Approval PRO BETA
🟡

Slowing Activity

No new clinical trials started in 1-2 years. Monitor for changes in pipeline strategy. Last trial started: 6/4/2024

31
Total Trials
9
Phase 3
16
Phase 2
0
Recruiting
284
Score

Pipeline by Phase

Phase 3
9
Phase 2
16
Phase 1
7

Therapeutic Focus

Pruritus Acne Vulgaris Prurigo Nodularis Healthy Atopic Dermatitis

Clinical Trials (31)

NCT02815267 Phase 3 COMPLETED

A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne

Started: 5/1/2016

NCT02815280 Phase 3 COMPLETED

A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne

Started: 5/1/2016

NCT03271021 Phase 3 COMPLETED

A Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 in the Treatment of Moderate-to-Severe Acne Vulgaris

Started: 7/17/2017

NCT03276936 Phase 3 COMPLETED

A Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 in the Treatment of Moderate to Severe Papulopustular Rosacea

Started: 9/5/2017

NCT03677401 Phase 3 COMPLETED

Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis

Started: 8/29/2018

NCT03546816 Phase 3 COMPLETED

Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis

Started: 5/2/2018

NCT03540160 Phase 3 TERMINATED

Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch)

Started: 3/15/2018

NCT03142451 Phase 3 COMPLETED

A Study (Study 1) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea

Started: 6/2/2017

NCT04608500 Phase 3 COMPLETED

A Study (Study 2) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea

Started: 6/1/2017

NCT06493578 Phase 2 TERMINATED

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VYN201 Gel in Subjects With Non-segmental Vitiligo.

Started: 6/4/2024

NCT01951274 Phase 2 COMPLETED

VPD-737 for Treatment of Chronic Pruritus

Started: 10/15/2013

NCT03343639 Phase 2 COMPLETED

Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Plaque Psoriasis

Started: 11/1/2017

NCT03841331 Phase 2 COMPLETED

Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Chronic Pruritus of Unknown Origin

Started: 1/22/2019

NCT00835718 Phase 2 TERMINATED

A Study of MK0594 in Patients With Alcohol Dependence (0594-020)

Started: 2/27/2009

NCT02196324 Phase 2 COMPLETED

A Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodularis (PN)

Started: 7/9/2014

NCT02975206 Phase 2 COMPLETED

Study of the Efficacy, Safety, and Tolerability of Serlopitant for Pruritus (Itch) in Atopic Dermatitis

Started: 11/1/2016

NCT03282591 Phase 2 COMPLETED

Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic Cough

Started: 10/3/2017

NCT02975271 Phase 2 TERMINATED

Study of the Efficacy, Safety & Tolerability of Serlopitant for Pruritus (Itch) After Burn Injury

Started: 11/1/2016

NCT04104685 Phase 2 COMPLETED

A Study to Compare FCD105 Foam to Minocycline 3% Foam, Adapalene 0.3% Foam and Vehicle Foam.

Started: 9/18/2019

NCT02239731 Phase 2 COMPLETED

Safety, Tolerability and Efficacy Study of Doxycycline Foam for the Prevention of EGFRI Skin Toxicity in Cancer Patients

Started: 10/1/2014

NCT02601963 Phase 2 COMPLETED

Safety and Efficacy Study of a Topical Minocycline Foam in Patients With Papulopustular Rosacea

Started: 9/1/2015

NCT01134991 Phase 2 TERMINATED

Study to Evaluate the Safety and Efficacy of Topical Minocycline FXFM244 in Rosacea Patients

Started: 6/1/2010

NCT01171326 Phase 2 COMPLETED

Study to Evaluate the Safety and Efficacy of Topical Minocycline FXFM244 in Impetigo Patients

Started: 8/1/2010

NCT01362010 Phase 2 COMPLETED

Clinical Study to Evaluate Tolerability and Safety of FXFM244 and to Monitor Clinical Effect in Acne Vulgaris Patients

Started: 1/1/2012

NCT04927572 Phase 1 COMPLETED

Safety, Pharmacokinetics and Efficacy of FMX114 Versus Vehicle in Adults With Atopic Dermatitis

Started: 10/13/2021

NCT03743038 Phase 1 COMPLETED

A Study Comparing Two Topicals in the Treatment of Acne Vulgaris

Started: 11/20/2018

NCT02250859 Phase 1 COMPLETED

A Pharmacokinetic Study of Minocycline in Male and Female Volunteers

Started: 9/1/2014

NCT04070742 Phase 1 COMPLETED

Dermal Phototoxicity Study

Started: 8/17/2016

NCT04070755 Phase 1 COMPLETED

Dermal Photo Allergic Skin Reaction

Started: 9/21/2016

NCT04064125 Phase 1 COMPLETED

Dermal Cumulative Irritant Patch Study

Started: 9/1/2016

NCT04052711 Phase 1 COMPLETED

A Randomized, Controlled Study to Evaluate the Sensitizing Potential of FMX-101 in Healthy Volunteers Using a Repeat Insult Patch Test Design

Started: 9/8/2016

Drug Candidates

VYN201 Gel Vehicle Gel FMX114 VPD-737 Placebo FMX-101, 4% minocycline foam Vehicle Foam FMX101 FMX103 1.5% 5 mg Serlopitant Tablets
Activity Status: Slowing
Last Trial Started: 6/4/2024
Last Trial Ended: 9/30/2025
Trials (12 months): 0
Completed Trials: 26
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.